Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric maltol versus ferric carboxymaltose for iron deficiency anaemia in inflammatory bowel disease
2015-002496-26Phase 3Completed
- Sponsor
- Shield Therapeutics plc
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in iron deficiency anemia (IDA) comparing Oral ferric maltol with Intravenous ferric carboxymaltose (2 arms). Primary endpoint: Hemoglobin response or normalization at Week 12. Started Sep 2015; status: completed.
02
Drugs
ferric maltolferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2015-002496-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002496-26.